In the following two decades, various small molecule DPP4 inhibitor substances have been developed and tested in subsequent clinical studies for the therapy of type 2 diabetes [19] and for other cardiovascular comorbidities [20,21,22]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.